膜联蛋白A5在不同临床分期的宫颈鳞癌组织中的表达

Expression of annexinA5 in uterine cervical carcionma of different clinical stages

目的检测膜联蛋白A5(ANXA5)在临床不同分期的宫颈癌组织中的表达差异,探讨膜联蛋白A5作为宫颈鳞癌分期标志物的可行性。方法采用国际妇产科协会(FIGO)的国际分期法,将病例分为Ⅰ期26例,Ⅱ期20例,Ⅲ期14例。用RT-PCR检测RNA水平ANXA5的表达情况;用Western blotting法和免疫组织化学法检测蛋白水平ANXA5的表达。组间结果采用t检验进行两两比较。结果 RT-PCR结果显示,随着临床分期增高,ANXA5 mRNA表达也增高,且3个分期的癌组织任意两组间差异均有显著性(P<0.05);Western blotting结果显示,Ⅰ期癌组织ANXA5的表达显著低于Ⅱ期和Ⅲ期癌组织(P<0.05);Ⅱ期和Ⅲ期癌组织ANXA5的表达没有显著性差异(P>0.05)。结论随着宫颈鳞癌组织临床分期的增高,膜联蛋白A5的表达也增高,具有宫颈鳞癌临床分期标志物的潜在可能。

Objective To study expression of annexinA5 （ANXAS） in uterine cervical squamous carcinoma of different clinical stages in order to explore the possibility of using ANXA5 as a clinical stage marker. Methods According to the international FIGO methods, the carcinoma tissues were classified as stages Ⅰ , Ⅱ and Ⅲ. RT-PCR method was used to determine the ANXA5 mRNA expression; Western boltting method and immunohistochemistry were employed to determine the protein expression. Comparisons between any two groups were analyzed by t-test. Results According to RTPCR, intensities for ANXA5 mRNA expression were lower at stage Ⅰ than at stages Ⅱ and Ⅲ （P 〈 0.05）. According to Western blotting, a total amount of ANXA5 protein was Ⅰ lower at stage Ⅰ than at stages Ⅱ and Ⅲ （P 〈 0. 05） , while there was no significant difference between stage Ⅱ and stage Ⅲ （P 〉 0.05 ）. Conclusion The intensities for both ANXA5 mRNA and it＇ s protein expression increase from stage Ⅰ to Ⅲ, suggesting that ANXA5 may, be a potential marker for classifying the uterine cervical aquamous carcinoma.